Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.57 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.57 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.57 |
| ▸ | GFRA3 | O60609 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | NNMT | P40261 | 1/20 | 0.35 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | UGT2B17 | O75795 | 2/20 | 0.33 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16763017 | 0.90 | CHRNB2 (0.51) | CHRNB2CHRNB4CHRNA4CHRNA2GFRA3 | |
| SCHEMBL29649333 | 0.77 | CHRNA7 (0.55) | CHRNB2CHRNB4CHRNA4CHRNA2GFRA3 | |
| SCHEMBL11713031 | 0.75 | CHRNB2 (0.46) | CHRNB2CHRNB4CHRNA4CHRNA2PPARD | |
| SCHEMBL11713808 | 0.74 | CHRNB2 (0.45) | CHRNB2CHRNB4CHRNA4CHRNA2NNMT | |
| SCHEMBL26307220 | 0.74 | GFRA3 (0.43) | CHRNB2CHRNB4CHRNA4CHRNA2GFRA3 | |
| SCHEMBL16800643 | 0.74 | GFRA3 (0.43) | CHRNB2CHRNB4CHRNA4CHRNA2GFRA3 | |
| SCHEMBL18094367 | 0.74 | GFRA3 (0.43) | CHRNB2CHRNB4CHRNA4CHRNA2GFRA3 | |
| SCHEMBL17691520 | 0.73 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA4CHRNA2CHRNA7 | |
| SCHEMBL29695532 | 0.72 | CHRNB2 (0.59) | CHRNB2CHRNB4CHRNA4CHRNA2 | |
| SCHEMBL1744686 | 0.72 | MAOA (0.50) | POLLCHRNA7CHRM4HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2880028-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-09-30 | — | — | EP | disclosed |
| EP-2880028-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-09-30 | — | — | EP | disclosed |
| US-9527875-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527875-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527875-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150191495-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2015-07-09 | — | — | US | disclosed |
| US-20150191495-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2015-07-09 | — | — | US | disclosed |
| US-20150191495-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2015-07-09 | — | — | US | disclosed |
| EP-2880028-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2015-06-10 | — | — | EP | disclosed |
| US-20140045746-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045746-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045746-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2014019186-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-06 | — | — | WO | disclosed |
| WO-2014022528-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045746-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR52 | CHRNB2 1777/4885CHRNB4 1746/4885CHRNA4 1167/4885 |
| US-20150191495-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR52 | CHRNB2 1777/4885CHRNB4 1746/4885CHRNA4 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.